DK1625142T3 - Markører for præcancer- og cancerceller og fremgangsmåde til interferering med celleproliferation deri - Google Patents

Markører for præcancer- og cancerceller og fremgangsmåde til interferering med celleproliferation deri

Info

Publication number
DK1625142T3
DK1625142T3 DK04752867.4T DK04752867T DK1625142T3 DK 1625142 T3 DK1625142 T3 DK 1625142T3 DK 04752867 T DK04752867 T DK 04752867T DK 1625142 T3 DK1625142 T3 DK 1625142T3
Authority
DK
Denmark
Prior art keywords
cancer
cancer cells
precancerous
markers
interfering
Prior art date
Application number
DK04752867.4T
Other languages
English (en)
Inventor
Luis O Burzio
Jaime E Villegas
Veronica A Burzio
Original Assignee
Andes Biotechnologies S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1625142(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Andes Biotechnologies S A filed Critical Andes Biotechnologies S A
Application granted granted Critical
Publication of DK1625142T3 publication Critical patent/DK1625142T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04752867.4T 2003-05-21 2004-05-21 Markører for præcancer- og cancerceller og fremgangsmåde til interferering med celleproliferation deri DK1625142T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47210603P 2003-05-21 2003-05-21
PCT/US2004/015929 WO2005001030A2 (en) 2003-05-21 2004-05-21 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein

Publications (1)

Publication Number Publication Date
DK1625142T3 true DK1625142T3 (da) 2011-08-08

Family

ID=33551438

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10171926.8T DK2270159T3 (da) 2003-05-21 2004-05-21 Markører for præ-cancerceller og cancerceller og en fremgangsmåde til at påvirke celleproliferation
DK10171933.4T DK2264170T3 (da) 2003-05-21 2004-05-21 Markører for præcancerøse celler og cancerceller og fremgangsmåde til at forstyrre sådanne cellers proliferation
DK04752867.4T DK1625142T3 (da) 2003-05-21 2004-05-21 Markører for præcancer- og cancerceller og fremgangsmåde til interferering med celleproliferation deri

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK10171926.8T DK2270159T3 (da) 2003-05-21 2004-05-21 Markører for præ-cancerceller og cancerceller og en fremgangsmåde til at påvirke celleproliferation
DK10171933.4T DK2264170T3 (da) 2003-05-21 2004-05-21 Markører for præcancerøse celler og cancerceller og fremgangsmåde til at forstyrre sådanne cellers proliferation

Country Status (13)

Country Link
US (6) US8318686B2 (da)
EP (3) EP2270159B1 (da)
JP (3) JP5201834B2 (da)
AT (1) ATE506437T1 (da)
BR (1) BRPI0410789B8 (da)
CA (1) CA2526639C (da)
DE (1) DE602004032329D1 (da)
DK (3) DK2270159T3 (da)
ES (3) ES2618210T3 (da)
HU (1) HUE032575T2 (da)
MX (1) MXPA05012620A (da)
PL (3) PL1625142T3 (da)
WO (1) WO2005001030A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1625142T3 (pl) 2003-05-21 2011-11-30 Andes Biotechnologies Global Inc Markery komórek przedrakowych i rakowych oraz sposób zaburzania proliferacji tych komórek
WO2006062389A2 (en) * 2004-10-29 2006-06-15 Primagen Holding B.V. Methods using mitochondrial nucleic acid for determining a health status of an individual
CN102589945B (zh) * 2012-02-16 2013-10-23 中国人民解放军第三军医大学第二附属医院 骨髓涂片存放盒
JP2016519083A (ja) * 2013-03-14 2016-06-30 アンデス バイオテクノロジーズ ソシエダード アノニマＡｎｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Ｓ．Ａ． 多発性骨髄腫を検出および処置するための方法
HUE042738T2 (hu) * 2013-03-14 2019-07-29 Andes Biotechnologies Global Inc Antiszensz oligonukleotidok rákos õssejtek kezelésére
WO2015066485A2 (en) * 2013-10-31 2015-05-07 The Children's Hospital Of Philadelphia Mitochondrial disease genetic diagnostics
EP3116513A4 (en) * 2014-03-14 2017-10-25 Andes Biotechnologies S.A. Pharmaceutical compositions comprising rna and use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6316210B1 (en) 1995-12-20 2001-11-13 Subsidiary No. 3, Inc. Genetic suppressor elements against human immunodeficiency virus
US6426412B1 (en) 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6720413B1 (en) 1997-03-04 2004-04-13 Musc Foundation For Research Development Methods and compositions for diagnosis and treatment of cancer
WO1998053319A2 (en) 1997-05-21 1998-11-26 The Johns Hopkins University Gene expression profiles in normal and cancer cells
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6537972B1 (en) 1997-06-02 2003-03-25 Subsidiary No. 3., Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6764822B1 (en) * 1997-09-19 2004-07-20 Sequenom, Inc. DNA typing by mass spectrometry with polymorphic DNA repeat markers
JP3251219B2 (ja) 1997-10-13 2002-01-28 雅嗣 田中 ヒトミトコンドリアｄｎａを用いた遺伝子検出方法
US6417169B1 (en) 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US7105639B2 (en) * 1998-05-15 2006-09-12 Genentech, Inc. Anti-PRO 4405 antibodies
WO1999065928A2 (en) 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US6280946B2 (en) 1998-08-07 2001-08-28 Boston Probes, Inc. PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya
WO2000026363A1 (en) * 1998-11-04 2000-05-11 Genset GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF
US6576759B2 (en) 1999-02-10 2003-06-10 Pangene Corporation Antisense inhibition of RAD51
JP2003521879A (ja) 1999-04-20 2003-07-22 マイトコー アルツハイマー病とともに分離するミトコンドリア遺伝子における一塩基多型
WO2001016323A2 (en) * 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US6673917B1 (en) 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
AU2002214487A1 (en) 2000-11-10 2002-05-21 Mitotech Ab Method for inducing apoptiosis
CN1322143C (zh) * 2000-12-04 2007-06-20 普里马根公司 检测线粒体核酸与核基因核酸比率确定药物活性和/或副作用的方法
US6573051B2 (en) * 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
US6544958B2 (en) 2001-03-26 2003-04-08 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1432823A4 (en) 2001-08-30 2005-03-02 Univ Emory MITOCHONDRIAL BIOLOGICAL EXPRESSION ARRAYS
PL1625142T3 (pl) 2003-05-21 2011-11-30 Andes Biotechnologies Global Inc Markery komórek przedrakowych i rakowych oraz sposób zaburzania proliferacji tych komórek
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples

Also Published As

Publication number Publication date
BRPI0410789A (pt) 2006-08-01
CA2526639A1 (en) 2005-01-06
US20210348236A1 (en) 2021-11-11
HUE032575T2 (en) 2017-10-30
US8318686B2 (en) 2012-11-27
WO2005001030A3 (en) 2005-12-22
US20160304971A1 (en) 2016-10-20
US8895719B2 (en) 2014-11-25
EP2264170A1 (en) 2010-12-22
EP1625142A4 (en) 2007-04-04
ATE506437T1 (de) 2011-05-15
ES2536002T3 (es) 2015-05-19
JP5775057B2 (ja) 2015-09-09
DK2270159T3 (da) 2015-04-20
US9903000B2 (en) 2018-02-27
JP2015096069A (ja) 2015-05-21
US20060241033A1 (en) 2006-10-26
US20150064700A1 (en) 2015-03-05
MXPA05012620A (es) 2006-05-25
DK2264170T3 (da) 2017-03-20
ES2365511T3 (es) 2011-10-06
PL2270159T3 (pl) 2015-08-31
EP1625142A2 (en) 2006-02-15
JP2013066478A (ja) 2013-04-18
US9359648B2 (en) 2016-06-07
JP2007519395A (ja) 2007-07-19
CA2526639C (en) 2018-03-20
BRPI0410789B8 (pt) 2021-05-25
PL2264170T3 (pl) 2017-08-31
US20130149371A1 (en) 2013-06-13
EP1625142B1 (en) 2011-04-20
EP2270159A1 (en) 2011-01-05
US20180340232A1 (en) 2018-11-29
BRPI0410789B1 (pt) 2020-11-10
DE602004032329D1 (de) 2011-06-01
WO2005001030A2 (en) 2005-01-06
EP2270159B1 (en) 2015-01-07
ES2618210T3 (es) 2017-06-21
EP2264170B1 (en) 2017-02-08
US10876166B2 (en) 2020-12-29
PL1625142T3 (pl) 2011-11-30
JP5201834B2 (ja) 2013-06-05

Similar Documents

Publication Publication Date Title
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
TW200519202A (en) Modulation of eIF4E expression
EA201171131A1 (ru) Усовершенствованное определение экспрессии генов
DE69533697D1 (de) ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION
PH12015500485A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer
EP1931806A4 (en) PKR ACTIVATION BY HYBRIDIZATION CHAIN REACTION
DK1490490T3 (da) Antisense IAP--nukleobase-oligomerer og anvendelser deraf
ATE546526T1 (de) Hybrid-interferenz-rna
BRPI0415302A (pt) uso de polimorfismos genéticos que se associam a eficácia de tratamento de doença inflamatória
WO2008073629A3 (en) Bifunctional predictors of cancer treatment sensitivity and resistance
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2005001138A3 (en) Breast cancer survival and recurrence
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2008051523A3 (en) Carbazole derivatives useful as medicaments in cancer therapy
WO2008087558A3 (en) Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
PL2270159T3 (pl) Markery dla komórek przedrakowych i rakowych oraz sposób zakłócania proliferacji tych komórek
WO2005047536A3 (en) Detection of genomic amplification and deletion in cancer
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
GB0418388D0 (en) Cell therapy
NO20053903D0 (no) Nukleotidlipidesterderivater.
WO2005001031A3 (en) Modulation of the rna interference pathway
WO2009115927A3 (en) Nucleotide analogues with quaternary carbon stereogenic centers and methods of use
EP1322658A4 (en) OLIGONUCLEOTIDE MODULATION OF HER-1 RECEPTOR EXPRESSION
EP1613775A4 (en) SELECTED RNA PATTERN FOR INDUCING CELL DEATH AND / OR APOPTOSIS
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)